Shanghai Junshi Biosciences Co Ltd

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates

Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications

Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients